Decatur Capital Management Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 101,590 shares of the biopharmaceutical company’s stock after selling 39,425 shares during the quarter. Gilead Sciences accounts for about 1.6% of Decatur Capital Management Inc.’s investment portfolio, making the stock its 20th biggest position. Decatur Capital Management Inc.’s holdings in Gilead Sciences were worth $6,439,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Advisors Preferred LLC bought a new stake in Gilead Sciences in the second quarter valued at about $26,000. Weaver Consulting Group bought a new stake in Gilead Sciences in the first quarter valued at about $34,000. Legacy Advisors LLC bought a new stake in Gilead Sciences in the second quarter valued at about $37,000. Evolution Wealth Advisors LLC bought a new stake in Gilead Sciences in the second quarter valued at about $46,000. Finally, Motco increased its holdings in Gilead Sciences by 213.6% in the second quarter. Motco now owns 690 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 470 shares during the last quarter. 79.57% of the stock is currently owned by institutional investors and hedge funds.
GILD stock traded up $0.76 during midday trading on Friday, reaching $64.02. The company had a trading volume of 2,774,184 shares, compared to its average volume of 6,046,392. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13. The stock has a 50 day moving average price of $64.11 and a 200 day moving average price of $65.34. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $76.44. The firm has a market capitalization of $81.13 billion, a PE ratio of 10.41, a P/E/G ratio of 2.93 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. Gilead Sciences’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.91 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 6.66 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.63 per share. The ex-dividend date was Thursday, September 12th. This represents a $2.52 annualized dividend and a dividend yield of 3.94%. Gilead Sciences’s dividend payout ratio is presently 40.98%.
GILD has been the subject of several research analyst reports. Raymond James set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Friday, August 23rd. JPMorgan Chase & Co. reissued a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a report on Wednesday, July 31st. Morgan Stanley set a $82.00 price objective on Gilead Sciences and gave the company a “hold” rating in a report on Monday, July 15th. Credit Suisse Group lowered their price objective on Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a report on Wednesday, July 31st. Finally, BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Friday, September 27th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $82.24.
In other news, Director Olsen Per Wold sold 4,908 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total transaction of $313,670.28. Following the completion of the transaction, the director now directly owns 102,762 shares in the company, valued at $6,567,519.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Brett A. Pletcher sold 608 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,716 shares of company stock valued at $821,299. Insiders own 0.20% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: Debt-To-Equity Ratio
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.